Citadel Advisors’s Candel Therapeutics CADL Stock Holding History

Citadel Advisors’s Portfolio CADL Stock Details CADL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$265K	Sell	54,100 -55,900	-51%	-$304K	﹤0.01%	10761
2025 Q4	$622K	Sell	110,000 -13,900	-11%	-$74.8K	﹤0.01%	8505
2025 Q3	$632K	Sell	123,900 -182,100	-60%	-$1.05M	﹤0.01%	8565
2025 Q2	$1.55M	Buy	306,000 +35,500	+13%	+$183K	﹤0.01%	6196
2025 Q1	$1.53M	Sell	270,500 -11,600	-4%	-$94.8K	﹤0.01%	6065
2024 Q4	$2.45M	Buy	282,100 +197,100	+232%	+$1.16M	﹤0.01%	5217
2024 Q3	$589K	Buy	85,000 +24,800	+41%	+$154K	﹤0.01%	7918
2024 Q2	$373K	Buy	+60,200	New	+$452K	﹤0.01%	8662

Other funds holding CADL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors's CADL Position: Q1 2026 in Review

Citadel Advisors reduced its Candel Therapeutics (CADL) stake by 68% in Q1 2026, selling an estimated $836K and leaving 72,666 shares worth $356K. The position accounts for ﹤0.01% of the portfolio, ranked #10084.

Citadel Advisors first reported a position in CADL in Q3 2022 and has held it in 10 quarters since. The position peaked at $2.53M in Q4 2024. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

Citadel Advisors held 72,666 shares of Candel Therapeutics worth $356K as of Q1 2026.
Citadel Advisors sold 153,690 Candel Therapeutics shares in Q1 2026, an estimated $836K.
Candel Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #10084 holding.
Citadel Advisors first reported a position in Candel Therapeutics in Q3 2022 and has held it in 10 quarters since.
Citadel Advisors's Candel Therapeutics position peaked at $2.53M in Q4 2024.
114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.